Immunome gets FDA IND clearance for IM-1340 solid-tumor ADC

Immunome says the FDA cleared its IND for IM-1340, a first-in-class antibody-drug conjugate for advanced solid tumors. A Phase 1 trial is slated to start in Q4 2026 to assess safety, pharmacokinetics and early anti-tumor activity; IM-1340 uses the HC74 topoisomerase I inhibitor payload.